Zacks Investment Management Immuno Gen, Inc. Transaction History

Zacks Investment Management

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $564,300 - $1.36 Million	-45,289 Reduced 83.83%	8,735 $258,000
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $81,806 - $115,365	5,806 Added 12.04%	54,024 $857,000
Q2 2023 Aug 15, 2023	BUY	$3.75 - $20.05 $19,725 - $105,463	5,260 Added 12.24%	48,218 $909,000
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $161,092 - $861,307	42,958 New	42,958 $810,000
Q4 2019 Feb 14, 2020	SELL	$2.25 - $5.8 $23,082 - $59,502	-10,259 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $74,070 - $113,107	-33,365 Reduced 76.48%	10,259 $25,000
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $60,256 - $110,470	33,476 Added 329.88%	43,624 $95,000
Q1 2019 May 15, 2019	SELL	$2.41 - $5.91 $2,843 - $6,973	-1,180 Reduced 10.42%	10,148 $28,000
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $9,794 - $24,114	-2,486 Reduced 18.0%	11,328 $54,000
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $118,800 - $155,545	13,814 New	13,814 $131,000
Q1 2018 May 14, 2018	SELL	$6.7 - $12.95 $131,279 - $253,742	-19,594 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $11,052 - $17,265	-2,180 Reduced 10.01%	19,594 $126,000
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $117,579 - $184,425	21,774	21,774 $167,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

Stay updated on Zacks Investment Management with notifications on news.